Login to Your Account



AHA Roundup


Thursday, November 17, 2011
• Idera Pharmaceuticals Inc., of Cambridge, Mass., announced the presentation of preclinical data indicating that its dual antagonist of Toll-like receptor (TLR) 7 and TLR9 reduced restenosis and atherosclerosis in a mouse model of hypercholesterolemia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription